Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2019 – CLL
ASH 2019 – CLL
Zanubrutinib Shows High Overall Response Rate and Durable Responses in CLL and SLL
ASH 2019 – CLL
Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor that has been shown to be potent and selective. Preliminary data suggest durable clinical responses in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More ›
Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
ASH 2019 – Wrap-up
,
ASH 2019 – CLL
Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read More ›
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia.
Read More ›
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Therapy
ASH 2019 – CLL
Chimeric antigen receptor (CAR) T-cells represent a novel and exciting strategy for patients with blood cancers. This study evaluated lisocabtagene maraleucel, an investigational CAR T-cell product, for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More ›
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL).
Read More ›
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
ASH 2019 – Wrap-up
,
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Read More ›
Venetoclax plus Rituximab in Relapsed/Refractory CLL: 4-Year Analysis
ASH 2019 – CLL
In a study that compared VenR (venetoclax plus rituximab) with standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), initial reports showed superior progression-free survival for VenR, as well as long-term benefits after patients stopped therapy.
Read More ›
Comparison of Therapies in Younger Patients with CLL
ASH 2019 – CLL
Results of the ECOG 1912 trial comparing chemoimmunotherapy with the oral BTK inhibitor ibrutinib plus rituximab in younger people with chronic lymphocytic leukemia (CLL).
Read More ›
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
ASH 2019 – Wrap-up
,
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Read More ›
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
ASH 2019 – Wrap-up
,
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs.
Read More ›
Page 2 of 4
1
2
3
4
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us